Fate Therapeutics said today it will develop off-the-shelf, chimeric antigen receptor (CAR)-targeted natural killer (NK) cell cancer immunotherapies through a research collaboration with the University of California, San Diego.

The collaboration—whose value was not disclosed—will be led by Dan S. Kaufman, M.D., Ph.D., director of cell therapy at UC San Diego School of Medicine and a professor of medicine in the school’s Division of Regenerative Medicine.

On November 30, Dr. Kaufman was awarded $5.15 million by the California Institute for Regenerative Medicine (CIRM) to advance clinical translation of NK cells derived from pluripotent stem cells into a standardized treatment for treating hematologic malignancies.

At the 59 th American Society of Hematology (ASH) Annual Meeting and Exposition on December 9, Dr. Kaufman and Fate Therapeutics are scheduled to present preclinical data highlighting CAR-targeted NK cells derived from an induced pluripotent stem cell (iPSC) engineered with a specific …